Looks back at real-world treatment of myeloma with daratumumab, lenalidomide and dexamethasone
Reviews past records of adults with myeloma, ineligible for transplant, given daratumumab, lenalidomide and dexamethasone.
Key facts
- Who runs it
- The Royal Wolverhampton Hospitals NHS Trust
- Where
- Wolverhampton, United KingdomSee the site
- Trial code
- Registry title
- REal World MAIA UK OutcomEs
- Status
- Not yet recruiting
- People taking part
- 300 people, planned
- Starts
- Dec 2026
- Expected to end
- Jul 2028
- Type of study
- Observational
- Record updated
- 15 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed multiple myeloma who could not have a stem cell transplant and received DRd (daratumumab, lenalidomide, dexamethasone) as first treatment in the UK.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Newly diagnosed multiple myeloma (NDMM), not able to have an autologous stem cell transplant at diagnosis
- Earlier treatment
- Must have received DRd as first treatment after NICE approval (after September 2023)
Main reasons for not taking part
- Took part in an interventional clinical trial for first-line therapy
- Not enough treatment or follow-up data for analysis
- DRd used for relapsed or refractory disease rather than newly diagnosed disease
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age ≥18 years
- Diagnosis of NDMM
- Not eligible for autologous stem cell transplant at diagnosis
- Received frontline DRd treatment following NICE approval (post-September 2023)
- Minimum 3 months of follow-up data available
Who cannot take part
- Participation in an interventional clinical trial for first-line therapy
- DRd used in relapsed/refractory setting rather than newly diagnosed disease
- Insufficient treatment or follow-up data for analysis
Where in United Kingdom
- The Royal Wolverhampton NHS TrustWolverhampton, United KingdomContact: Tanweer AhmedNo longer taking part
About the trial
What the trial wants to find out
This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Retrospective Study of Clinical Outcomes in Newly Diagnosed, Transplant Ineligible Multiple Myeloma Patients Treated With Daratumumab, Lenalidomide and Dexamethasone (DRd) Outside of Clinical Trials in the UK
- Plain-language title
- Looks back at real-world treatment of myeloma with daratumumab, lenalidomide and dexamethasoneGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 15 September 2026